Skip to main content
. 2018 Jul 23;3(5):e000388. doi: 10.1136/esmoopen-2018-000388

Table 3.

Adverse events (≥20% incidence) regardless of study drug relationship by preferred term (safety set) − overall (dose-escalation phase+follow-up phase)

Preferred term All patients, n (%)
Diarrhoea 5 (50)
Nausea 5 (50)
Fatigue 3 (30)
Hyperglycaemia 3 (30)
Hypophosphatemia 3 (30)
Chills 2 (20)
Tumour pain 2 (20)
Weight decreased 2 (20)